SAN DIEGO, June 21 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA)
today announced the appointment of Mark W. Schwartz, Ph.D. to the position of
vice president of commercial operations and chief commercial officer.
Dr. Schwartz will be responsible for business development, and sales and
marketing, and will report to Michael G. Grey, president and chief executive
officer.
Dr. Schwartz brings fourteen years of sales, marketing and business
development experience to Trega. Most recently, Dr. Schwartz was vice
president of marketing and business development for Argonaut Technologies
where he built a marketing infrastructure and developed a long-term strategy
for growth. Prior to that, he was vice president of marketing and business
development at Synteni, Inc., where he developed and implemented its business
strategy prior to its acquisition by Incyte Pharmaceuticals. Prior to his
tenure at Synteni, Dr. Schwartz served as vice president and general manager
of Accelerated Discovery Services, a flagship business unit of Tripos, Inc.
Dr. Schwartz also held marketing positions at BIOSYM Technologies and Applied
Biosystems.
"We are delighted to have Mark as part of our business development team,"
said Michael G. Grey, president and chief executive officer. "With his
experience and contacts in the industry Mark will be a great asset in
marketing our Chem.Folio(TM) and NaviCyte products, as well as partnering our
research programs."
"Trega has a broad technology base," commented Dr. Schwartz. "Its focus
on both discovering lead compounds and developing novel selection technologies
uniquely positions the company to capture a broad array of both product and
partnering opportunities. I look forward to working with the Trega team."
Trega Biosciences is focused on accelerating the process of drug discovery
from disease targets to clinical candidates by using small molecule
combinatorial chemistry, high throughput screening and predictive
bioinformatics to rapidly create novel drug candidates having greater chances
of clinical success. In combination with its wholly owned subsidiary,
NaviCyte, Trega offers integrated products and services spanning the drug
discovery process -- beginning with synthesizing novel compounds to providing
uniquely qualified drug leads -- to the pharmaceutical and biopharmaceutical
industries. Trega also uses its drug discovery technologies in its internal
development programs, which are focused on discovering small molecules acting
on melanocortin receptors, which may be important in the treatment of
inflammatory and metabolic diseases.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether the impending transition in
management will occur without disrupting the Company's business and operation,
whether any proposed product can be successfully formulated, scaled-up,
developed, and commercialized, whether regulatory approvals can be obtained,
the impact of competitive products and pricing, the financial condition of the
Company in the future, whether any corporate collaborations or alliances will
be successful, and other risks detailed from time to time in Trega's
Securities and Exchange Commission filings. These forward-looking statements
represent Trega's judgment as of the date of this release. Actual results may
differ materially from those projected. Trega disclaims, however, any intent
or obligation to update these forward-looking statements.
Trega's releases are on the World Wide Web at http://www.trega.com and
PR Newswire's fax-on-demand service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
 back to top
Related links:
http://www.trega.com
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Gerard A. Wills, Chief Financial Officer of
Trega Biosciences, Inc., 619-410-6695
|
